Analysts See $-0.57 EPS for Caladrius Biosciences, Inc. (CLBS)

July 14, 2018 - By Nellie Rakes

Analysts expect Caladrius Biosciences, Inc. (NASDAQ:CLBS) to report $-0.57 EPS on August, 9.They anticipate $0.31 EPS change or 35.23 % from last quarter’s $-0.88 EPS. After having $-0.52 EPS previously, Caladrius Biosciences, Inc.’s analysts see 9.62 % EPS growth. The stock increased 13.19% or $0.72 during the last trading session, reaching $6.18. About 229,982 shares traded. Caladrius Biosciences, Inc. (NASDAQ:CLBS) has declined 13.09% since July 14, 2017 and is downtrending. It has underperformed by 25.66% the S&P500.

Caladrius Biosciences, Inc. (NASDAQ:CLBS) Ratings Coverage

Among 2 analysts covering Caladrius Biosciences (NASDAQ:CLBS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Caladrius Biosciences had 7 analyst reports since January 19, 2018 according to SRatingsIntel. As per Friday, January 19, the company rating was maintained by H.C. Wainwright. H.C. Wainwright maintained the shares of CLBS in report on Wednesday, June 6 with “Buy” rating. The stock has “Buy” rating by H.C. Wainwright on Wednesday, March 14. The firm has “Buy” rating by Chardan Capital Markets given on Friday, March 23. H.C. Wainwright maintained Caladrius Biosciences, Inc. (NASDAQ:CLBS) rating on Wednesday, June 20. H.C. Wainwright has “Buy” rating and $1200 target. H.C. Wainwright maintained Caladrius Biosciences, Inc. (NASDAQ:CLBS) rating on Tuesday, March 6. H.C. Wainwright has “Buy” rating and $7.0 target. H.C. Wainwright maintained the shares of CLBS in report on Friday, May 11 with “Buy” rating.

More notable recent Caladrius Biosciences, Inc. (NASDAQ:CLBS) news were published by: Streetinsider.com which released: “Caladrius Biosciences (CLBS) Granted FDA Regenerative Medicine Advanced Therapy Designation for CD34+ Cell …” on June 19, 2018, also Benzinga.com with their article: “50 Biggest Movers From Yesterday” published on June 21, 2018, Benzinga.com published: “Benzinga’s Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street” on June 21, 2018. More interesting news about Caladrius Biosciences, Inc. (NASDAQ:CLBS) were released by: Benzinga.com and their article: “38 Stocks Moving In Wednesday’s Mid-Day Session” published on June 20, 2018 as well as Benzinga.com‘s news article titled: “Caladrius Shares Extend Rally After FDA Grants Special Status To Cell Therapy” with publication date: June 20, 2018.

Caladrius Biosciences, Inc. (NASDAQ:CLBS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.